Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: SANUWAVE is an emerging global regenerative medicine company developing non-invasive, biological response activating devices using Pulsed Acoustic Cellular Expression (PACE) technology. The company focuses on wound healing (lead product: dermaPACE), orthopedic/spine, plastic/cosmetic, and cardiac applications. The company is a smaller reporting company and is no longer a shell company following a 2009 reverse merger.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenues | $728,446 | $660,725 |
| Gross Profit | $478,120 | $434,935 |
| Gross Margin | 66% | 66% |
| Net Loss | $(14,922,441) | $(6,153,040) |
| Loss Per Share (Basic & Diluted) | $(1.15) | $(0.54) |
| Cash and Cash Equivalents (Year End) | $417,457 | $1,786,369 |
| Working Capital Deficiency | $(7,029,635) | $(187,459) |
| Accumulated Deficit | $(54,270,031) | $(39,347,590) |
| Total Debt (Notes Payable) | $9,620,033 | $8,887,981 |
Note: Revenues are derived primarily from European sales of CE Marked devices (orthoPACE and Evotron). The company has no commercial products in the United States as of the reporting date.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10% to $728,446, driven by European sales of the new orthoPACE device and legacy Evotron devices.
- Net Loss Expansion: Net loss more than doubled to $14.9 million from $6.2 million. This was primarily due to:
- Stock-Based Compensation: Non-cash stock compensation expense in General and Administrative (G&A) expenses increased by $1.96 million to $3.04 million.
- Debt Extinguishment: A one-time loss of $2.69 million was recorded upon exchanging promissory notes for equity units.
- Asset Write-downs: Depreciation increased 127% and a $169,581 write-down of assets held for sale (Ossatron devices) was recorded.
- Liquidity Deterioration: Cash decreased by $1.37 million. The company moved from a minor working capital deficiency in 2009 to a significant deficiency of $7.03 million in 2010.
- Restatement: The company restated 2008 and 2009 financial statements to correct an understatement of $687,309 in stock-based compensation expense related to 2008 options.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- dermaPACE PMA: The company expects to file the final module of its Pre-Market Approval (PMA) application with the FDA in Q2 2011, pending which it anticipates a U.S. launch in early 2012.
- Capital Needs: Management expects to continue incurring significant losses and requires additional capital to fund R&D, clinical trials, and commercialization. There is no assurance that financing will be available.
- Going Concern: The company has a substantial doubt about its ability to continue as a going concern due to operating losses and working capital deficiency.
Risks and Contingencies
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the accounting for complex financial instruments and stock-based compensation.
- Intellectual Property: A third party (SwiTech Medical AG) filed a reexamination request against a key U.S. patent. While the company reached an agreement for amended claims, the outcome remains uncertain.
- Regulatory Approval: Success depends on FDA approval of dermaPACE. The FDA maintains the technology as a Class III device requiring a PMA.
- Concentration of Ownership: Prides Capital Fund I, LP and NightWatch Capital Partners II, LP control approximately 65% of the outstanding common stock.
Unusual Items
- Debt-for-Equity Swap: In October 2010, $2.52 million in promissory notes (principal and interest) were exchanged for equity units, resulting in a $2.69 million loss on extinguishment of debt.
- Government Grant: The company received a $244,479 cash grant under the U.S. government's Qualifying Therapeutic Discovery Project (QTDP) program.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $417,457 cash balance against the projected burn rate for the dermaPACE PMA filing and subsequent commercialization.
- Financing Terms: Review the terms of any new equity or debt financing required to address the $7 million working capital deficiency.
- FDA Timeline: Monitor the status of the dermaPACE PMA application filing (expected Q2 2011) and FDA response.
- Patent Status: Confirm the final resolution of the SwiTech Medical AG patent reexamination proceedings.
- Internal Controls: Assess the progress of the remediation plan for the material weaknesses in internal controls over financial reporting.